Sabine Hertle

437 total citations
8 papers, 189 citations indexed

About

Sabine Hertle is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Sabine Hertle has authored 8 papers receiving a total of 189 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Hematology, 5 papers in Genetics and 3 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Sabine Hertle's work include Chronic Lymphocytic Leukemia Research (5 papers), Chronic Myeloid Leukemia Treatments (5 papers) and Acute Myeloid Leukemia Research (3 papers). Sabine Hertle is often cited by papers focused on Chronic Lymphocytic Leukemia Research (5 papers), Chronic Myeloid Leukemia Treatments (5 papers) and Acute Myeloid Leukemia Research (3 papers). Sabine Hertle collaborates with scholars based in Switzerland, Italy and United States. Sabine Hertle's co-authors include Michele Baccarani, Jianxiang Wang, Ming Hou, Amer M. Zeidan, Jianda Hu, Zhixiang Shen, Yu Hu, Aristoteles Giagounidis, Giuseppe Saglio and Valeria Santini and has published in prestigious journals such as Blood, British Journal of Cancer and Future Oncology.

In The Last Decade

Sabine Hertle

8 papers receiving 188 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sabine Hertle Switzerland 5 139 100 49 45 33 8 189
Michelina Santopietro Italy 9 178 1.3× 155 1.6× 59 1.2× 23 0.5× 12 0.4× 37 234
José Antonio Queizán Spain 7 103 0.7× 48 0.5× 21 0.4× 58 1.3× 19 0.6× 13 169
Laura Gallur Spain 6 184 1.3× 69 0.7× 14 0.3× 55 1.2× 45 1.4× 18 266
Anna Lübking Sweden 9 156 1.1× 109 1.1× 66 1.3× 55 1.2× 38 1.2× 14 236
Arta Dreimane Sweden 9 296 2.1× 246 2.5× 123 2.5× 74 1.6× 50 1.5× 17 347
Alicia Enrico Argentina 5 198 1.4× 177 1.8× 117 2.4× 33 0.7× 26 0.8× 13 227
Amir T. Fathi United States 7 175 1.3× 95 0.9× 20 0.4× 32 0.7× 20 0.6× 24 233
Bartlomiej Getta United States 6 184 1.3× 117 1.2× 17 0.3× 31 0.7× 54 1.6× 19 236
Yasufumi Kawasaki Japan 9 93 0.7× 36 0.4× 24 0.5× 33 0.7× 20 0.6× 19 173
Natalie Ertz-Archambault United States 4 42 0.3× 27 0.3× 19 0.4× 45 1.0× 13 0.4× 13 145

Countries citing papers authored by Sabine Hertle

Since Specialization
Citations

This map shows the geographic impact of Sabine Hertle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sabine Hertle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sabine Hertle more than expected).

Fields of papers citing papers by Sabine Hertle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sabine Hertle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sabine Hertle. The network helps show where Sabine Hertle may publish in the future.

Co-authorship network of co-authors of Sabine Hertle

This figure shows the co-authorship network connecting the top 25 collaborators of Sabine Hertle. A scholar is included among the top collaborators of Sabine Hertle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sabine Hertle. Sabine Hertle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Zeidan, Amer M., Aristoteles Giagounidis, Mikkael A. Sekeres, et al.. (2023). STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2. Future Oncology. 19(9). 631–642. 23 indexed citations
2.
3.
Gelderblom, Hans, Robin L. Jones, Suzanne George, et al.. (2020). Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study. British Journal of Cancer. 122(8). 1158–1165. 21 indexed citations
4.
Zeidan, Amer M., Jordi Esteve, Aristoteles Giagounidis, et al.. (2020). The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML). Blood. 136(Supplement 1). 45–46. 23 indexed citations
5.
Hijiya, Nobuko, Alexey Maschan, Carmelo Rizzari, et al.. (2019). Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia. Blood. 134(23). 2036–2045. 37 indexed citations
6.
Hijiya, Nobuko, Antonella Colombini, Hiroyuki Shimada, et al.. (2019). PF412 A PHASE 2 STUDY OF NILOTINIB (NIL) IN PEDIATRIC PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME–POSITIVE CHRONIC MYELOID LEUKEMIA (CML): SAFETY UPDATE AFTER 36 CYCLES OF TREATMENT. HemaSphere. 3(S1). 158–158. 2 indexed citations
7.
8.
Wang, Jianxiang, Zhixiang Shen, Giuseppe Saglio, et al.. (2015). Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood. 125(18). 2771–2778. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michelina Santopietro Breakdown of academic impact, for papers by José Antonio Queizán Breakdown of academic impact, for papers by Laura Gallur Breakdown of academic impact, for papers by Anna Lübking Breakdown of academic impact, for papers by Arta Dreimane Breakdown of academic impact, for papers by Alicia Enrico Breakdown of academic impact, for papers by Amir T. Fathi Breakdown of academic impact, for papers by Bartlomiej Getta Breakdown of academic impact, for papers by Yasufumi Kawasaki Breakdown of academic impact, for papers by Natalie Ertz-Archambault
Rankless by CCL
2026